All News

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from February as an alternative to more complex and time-consuming regimens in the setting of relapsed/refractory large B-cell lymphoma (R/R LBCL).

A series of new studies from the National Kidney Foundation Spring Clinical Meeting exhibit the association between impaired kidney function and prolonged hospital stays, higher charges, and greater resource utilization.

New drug delivery technologies, such as nanoparticles, hydrogels, and self-powered microgrippers, are showing great potential for enhancing targeted treatment and sustained release of medications in the gastrointestinal (GI) tract, particularly for managing inflammatory bowel disease (IBD).

Study participants treated with elinzanetant experienced significantly reduced hot flash frequency vs paroxetine, desvenlafaxine, and gabapentin in a new meta-analysis.

As Medicare Advantage (MA) enrollment grows, Johnie Rose, MD, PhD, Case Western Reserve University School of Medicine, underscores the importance of ongoing research into outcomes for MA beneficiaries vs fee-for-service (FFS) Medicare beneficiaries.

With deadlines looming in 2026 and 2027 for compliance with the CMS Advancing Interoperability and Improving Prior Authorization Final Rule, a survey indicates a concerning lack of readiness among payers and providers to meet the new requirements for data sharing.

In this fourth part of a discussion with The American Journal of Managed Care®, Andrew Kuykendall, MD, clinical researcher at Moffitt Cancer Center and VERIFY investigator, speaks to the impressive patient-reported outcomes seen thus far.

Investigators highlighted Raman spectroscopy, a noninvasive diagnostic technology that could lead to faster, earlier detection of skin cancer.

Joseph Saseen, PharmD, discussed the importance of knowing lipoprotein a (Lp[a]) levels to enable clinicians to provide the best patient care and spread awareness to those who might be affected.

New data presented at the 2025 World Congress of Pediatric Dermatology annual meeting highlights the efficacy and safety of once-daily icotrokinra (JNJ-2113) in adolescents with moderate to severe plaque psoriasis.

Vegetables, fish oil, fruit, and high-fiber foods have anti-inflammatory effects, while low-fiber bread and animal fats are associated with pro-inflammatory effects. Diets heavier on these pro-inflammatory foods may be associated with higher risks of brain disorders.

Patients with chronic lymphocytic leukemia (CLL) who experience Richter transformation have a poor prognosis, but ibrutinib may help boost the efficacy of chimeric antigen receptor T-cell therapies.

A report published today by Shatterproof and The Bowman Family Foundation underscores the potential of the collaborative care model to lower suicide risk across diverse patient populations and health systems.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

Excessive use of digital devices and mental health issues can both contribute to the development of dry eye syndrome.

New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers to accessing health care.

Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in nonmetropolitan areas, and were unmarried had higher odds of refusing cytoreductive surgery.

Carla Nester, MD, MSA, FASN, is coinvestigator for the ongoing APPEAR-C3G trial (NCT04817618), data from which were used to support the FDA’s recent approval of iptacopan (Fabhalta; Novartis) in complement 3 glomerulopathy (C3G).

Experts agree that the expansion of telehealth was one of the most significant positive outcomes of the COVID-19 pandemic.

The randomized control period of the MINT trial has completed, and these newest data describe outcomes among patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (AChR+ gMG), explained MINT principal investigator Richard Nowak, MD, MS, Yale School of Medicine.

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic diseases, as outlined at the Academy of Managed Care Pharmacy annual meeting.

Hospitalized patients with opioid use disorder (OUD) who received in-hospital addiction consultation services were more likely to receive evidence-based OUD care, a new study found.

Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.

The analysis supports the integration of sodium-glucose cotransporter 2 (SGLT2) inhibitors into treatment paradigms for patients with chronic kidney disease (CKD) not only for their established benefits but also for addressing anemia.

The combination of nivolumab with ipilimumab was approved for unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.